Slide 1: Lacutamab KOL event
Lacutamab KOL event 11 June 2024
Slide 2: Disclaimer on Forward-Looking Information and Risk Factors
Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. 2
Slide 3: Participants on Today's Call
Participants on Today’s Call Sonia Quaratino Pierluigi Porcu Susan Thornton MD, PhD MD (Q&A) Chief Medical Officer of Director, Division of Hematologic Innate Pharma Malignancies and Hematopoietic CEO Cutaneous Lymphoma Stem Cell Transplantation, Sidney Foundation Kimmel Cancer Center, Jefferson Hea
Slide 4: Agenda
Agenda 1 Introduction – Dr. Quaratino 2 Results from the Phase 2 TELLOMAK study in Mycosis Fungoides (ASCO 2024) – Dr. Porcu 3 Summary - Dr. Quaratino 4 Q&A 4
Slide 5: Scientific innovation drives our strategy
Scientific innovation drives our strategy Lacutamab ANKET® & ADC Monalizumab Our ambition – leverage our scientific know-how in innate IPH6501 at ASCO Phase 2 MF at Phase 3 trial immunity and antibody engineering to IPH45 ADC at AACR ASCO, continue to underway, further develop cancer drugs that impr
Slide 6: Our robust pipeline of proprietary & partnered assets
Our robust pipeline of proprietary & partnered assets Program Target Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Comments Lacutamab KIR3DL2 Sezary syndrome / MF Phase 2 TELLOMAK (FDA FAST TRACK/EMA PRIME DESIGNATION) MF data ASCO 2024 Monoclonal antibodies PTCL Phase 2 KILT IST with LYSA IPH5301
Slide 7: Five abstracts selected for ASCO 2024
Five abstracts selected for ASCO 2024 IPH6501 Lacutamab Monalizumab IL2v-armed Tetra-specific Anti KIR3DL2 mAb Anti NKG2A mAb ANKET® targeting CD20 Phase 2 TELLOMAK Phase 1/2 Phase 2 COAST Trial-In-Progress Updated Phase 2 results Top-line phase 2 results IPH6501 in R/R CD20-expressing Durvalumab ±
Slide 8: Lacutamab | Clinical Trials
LACUTAMAB Lacutamab | Clinical Trials A potential new standard of care in the T-cell lymphomas expressing KIR3DL2 Cutaneous T cell lymphoma TELLOMAK Sézary syndrome Phase 2 Trial Sézary syndrome 80-200 patients Phase 2 >90% KIR3DL2 expression N=56 N~100 ASH 2023 Minimum of 2 prior Cohort 2 Cohort 3
Slide 9: Agenda
Agenda 1 Introduction – Dr. Quaratino 2 Results from the Phase 2 TELLOMAK study in Mycosis Fungoides (ASCO 2024) – Dr. Porcu 3 Summary - Dr. Quaratino 4 Q&A 9
Slide 10: Lacutamab in Patients with Relapsed and/or Refractory Mycosis Fungoides: Results from the TELLOMAK phase 2 trial
Lacutamab in Patients with Relapsed and/or Refractory Mycosis Fungoides: Results from the TELLOMAK phase 2 trial Martine Bagot1, Caroline Ram-Wolff1, Youn H Kim2, Auris Huen3, Stéphane Dalle4, Brian Poligone5, Neha Mehta-Shah6, Anne-Benedicte Duval Modeste7, Pier Luigi Zinzani8, Sherida Woei-A-Jin9,
Slide 11: Mycosis Fungoides
Mycosis Fungoides • MF is the most common subtype of CTCL • About 25% of patients are diagnosed in advanced stage 2 (IIB-IVB), with 5-year survival 15-25% • Mogamulizumab1 was the last drug approval (2018) in R/R CTCL indicated for the treatment of patients after >1 prior systemic therapies — ORR in
Slide 12: Lacutamab: First-in-class humanized anti-KIR3DL2 antibody
Lacutamab First-in-class humanized anti-KIR3DL2 antibody • KIR3DL2 is a killer immunoglobulin-like receptor, expressed in 90% of SS pts and 50% of MF pts* • Lacutamab is a first-in-class monoclonal antibody designed to specifically deplete KIR3DL2- expressing cells via antibody-dependent cellular
Slide 13: TELLOMAK: Phase 2 Study in Sezary Syndrome and Mycosis Fungoides
TELLOMAK : Phase 2 Study in Sezary Syndrome and Mycosis Fungoides Mycosis Fungoides (N~107) ≥ 2 prior systemic therapies Cohort 2 Cohort 3 All Comers KIR3DL2 KIR3DL2≥ 1% EXPRESSION KIR3DL2 <1% KIR3DL2 ≥ 1% Simon 2 Stage Simon 2 Stage or <1% Key Eligibility Criteria • Relapsed and/or refractory stage
Slide 14: Patient baseline characteristics in MF patients (n=107)
TELLOMAK Patient baseline characteristics in MF patients (n=107) All MF KIR3DL2 ≥ 1% KIR3DL2 <1% N=107 N=48 N=59 Age in years, Median (range) 62 (19-82) 59 (28-82) 65 (19-81) Sex 72 (67.3) 28 (58.3) 44 (74.6) • Male, N (%) 35 (32.7) 20 (41.7) 15 (25.4) • Female, N (%) Stage at baseline, N (%) • I 44
Slide 15: Efficacy results in MF patients and by KIR3DL2 expression level
TELLOMAK Efficacy results in MF patients (N=107) and by KIR3DL2 expression level All MF KIR3DL2 ≥ 1% KIR3DL2 <1% ITT set N=107 N=48 N=59 16.8% 20.8% 13.6% Olsen 2011 Global ORR % (95%CI) (10.9, 25.0) (11.7, 34.3) (7.0, 24.5) CR n (%) 2 (1.9) 2 (4.2) 0 (0.0) PR n (%) 16 (15.0) 8 (16.7) 8 (13.6) SD* n
Slide 16: Waterfall plot for Best Overall Response by KIR3DL2 Expression Level
TELLOMAK Waterfall plot for Best Overall Response by KIR3DL2 Expression Level Response criteria based on Olsen 2011 KIR3DL2 ≥ 1% (N=48) KIR3DL2 <1% (N=59) • 20.8% patients achieved Global Response, including 2 CR and • 13.6% patients achieved Global Response, including 8 PR 8 PR (95% CI 11.7, 34.3)
Slide 17: Efficacy results in MF patients: PFS including by KIR3DL2 Expression Level
TELLOMAK Efficacy results in MF patients: PFS including by KIR3DL2 Expression Level All MF KIR3DL2 ≥ 1% KIR3DL2 <1% PFS in months 10.2 12.0 8.5 Median, (95%CI) (6.5, 16.8) (5.6, 20.0) (6.5, 17.5) Alive without % (95% CI) % (95% CI) % (95% CI) progression • 6 months • 65.3 (54.7, 74.0) • 64.5 (48.0,
Slide 18: Patient Case
TELLOMAK Patient Case Patient BASELINE Week 57 characteristics October 05, 2020 March 29, 2022 • 68-year-old female • MF diagnosed in 2016 • 4 previous lines of therapy (PUVA therapy, bexarotene, interferon, methotrexate) • T2N0M0B1 at baseline • Response: — Skin: PR from W5, CR from W37 — Blood: CR
Slide 19: Patient Case
TELLOMAK Patient Case Patient December 07, 2021 March 30, 2023 characteristics • 74-year-old male • MF diagnosed in 2020 • 2 previous lines of therapy (bexarotene, extracorporeal photopheresis) • T2BN2M0B1 at baseline • Response: — Skin: PR from W5 until W69 — Blood: PR from W13 — LN: SD (N2 at base
Slide 20: Summary of adverse events
TELLOMAK Summary of adverse events All MF KIR3DL2 ≥ 1% KIR3DL2 <1% Patients with at least one N=107 N=48 N=59 TEAE 97 (90.7) 43 (89.6) 54 (91.5) Related1 TEAE 62 (57.9) 29 (60.4) 33 (55.9) TESAE 25 (23.4) 13 (27.1) 12 (20.3) Related TESAE 4 (3.7) 2 (4.2) 2 (3.4) Grade >3 TEAE 26 (24.3) 13 (27.1) 13
Slide 21: Most Common Related Adverse Events
TELLOMAK Most Common Related Adverse Events Related TEAE All MF KIR3DL2 ≥ 1% KIR3DL2 <1% Most frequent (>5%) or N=107 N=48 N=59 of interest, n (%) Fatigue 12 (11.2) 7 (14.6) 5 (8.5) Nausea 12 (11.2) 4 (8.3) 8 (13.6) Asthenia 11 (10.3) 5 (10.4) 6 (10.2) Arthralgia 11 (10.3) 5 (10.4) 6 (10.2) Diarrhea
Slide 22: KIR3DL2 expression on MF patients
KIR3DL2 expression on MF patients KIR3DL2 Biopsy 1 Biopsy 2 1.3% KIR3DL2+ 60% KIR3DL2+ • Intra-patient variability observed between biopsies Patient A • 34/107 (32%) MF patients had only 1 biopsy for KIR3DL2 status determination • Ongoing biomarker analyses from MF patients 0.8% KIR3DL2+ 26% KIR3DL2
Slide 23: MF Conclusions
TELLOMAK MF Conclusions • TELLOMAK is a Phase 2 study evaluating lacutamab monotherapy in CTCL. The study enrolled MF patients with ≥ 2 prior systemic therapies • In the MF population — Lacutamab treatment induced early responses in heavily pretreated patients with MF — Anti-tumor activity was obser
Slide 24: With Thanks
TELLOMAK - NCT03902184 With Thanks 53 active sites • USA (17) • France (10) • Germany (8) • Spain (6) • Italy (4) • Belgium (3) • Poland (3) • Austria (2) Study sponsored by Innate Pharma Thank you to all our investigators, experts, site staff, and ultimately the patients and their families 24
Slide 25: Agenda
Agenda 1 Introduction – Dr. Quaratino 2 Results from the Phase 2 TELLOMAK study in Mycosis Fungoides (ASCO 2024) – Dr. Porcu 3 Summary - Dr. Quaratino 4 Q&A 25
Slide 26: MAVORIC Phase 3 trial: mogamulizumab vs. vorinostat in previously-treated CTCL
MAVORIC Phase 3 trial: mogamulizumab vs. vorinostat in previously-treated CTCL MAVORIC Subgroups exploratory analysis – MF subgroup MF Vorinostat Mogamulizumab n = 99 n = 105 ORR % 7.1 21 PFS in months 3.10 [2.87 – 4.70] 5.40 [3.97 – 7.57] Median (95% CI) After ≥ 1 systemic therapy HAS - Direction d
Slide 27: TELLOMAK data provides increased confidence in lacutamab potential
TELLOMAK data provides increased confidence in lacutamab potential In terms of CTCL segments & longer duration of treatment ~ 1,500 ~3,500 ~5,000 All Comers All Comers KIR3DL2 KIR3DL2 w/Subgroup Analysis w/Subgroup Analysis <1% ≥ 1% ≥1 ≥1 Prior Prior line line MF & SS ≥1 Prior All-comers SS [95% exp
Slide 28: Newsflow and upcoming catalysts
Newsflow and upcoming catalysts • Monalizumab PACIFIC-9 | Phase 3 readout (AZ) Delivering across our strategic objectives • Monalizumab NeoCOAST-2 | Phase 2 readout (AZ) • IPH5201 (CD39) MATISSE | Phase 2 readout (AZ) • IPH5301 (CD73) | Phase 1 data • SAR’579 / IPH6101 ANKET® (CD123) | Next steps (S
Slide 29: Innate Key Pillars
Innate Key Pillars Create value for patients and shareholders Established expertise in immuno-oncology • LACUTAMAB TELLOMAK DATA • First results in mycosis fungoides shared at ASCO 2024, results in SS shared at ASH 2023 • Planning for FDA interaction for a fast to market strategy • EXPAND ANKET® CLI
Slide 30: Agenda
Agenda 1 Introduction – Dr. Quaratino 2 Results from the Phase 2 TELLOMAK study in Mycosis Fungoides (ASCO 2024) – Dr. Porcu 3 Summary - Dr. Quaratino 4 Q&A 30
Slide 31: Thank you
Thank you www.innate-pharma.com investors@innate-pharma.fr EURONEXT : IPH.PA NASDAQ : IPHA